




# SUVEN LIFE SCIENCES LTD

Off: SDE Serene Chambers, 6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

## STATEMENT OF UN AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & SIX MONTHS ENDED SEPTEMBER 30, 2023.

Rs. In Lakhs

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the Six Months period ended		For the year ended
		30/09/2023	30/06/2023	30/09/2022	30/09/2023	30/09/2022	31/03/2023
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	<b>Income</b>						
	Revenue from operations	305.96	379.73	438.65	685.69	792.57	1,353.92
	Other Income	514.17	563.96	20.61	1,078.13	64.19	844.90
	<b>Total income</b>	<b>820.13</b>	<b>943.69</b>	<b>459.26</b>	<b>1,763.82</b>	<b>856.76</b>	<b>2,198.82</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	421.26	453.72	439.67	874.98	855.54	1,577.04
	d) Finance costs	4.19	5.12	6.94	9.31	17.11	28.91
	e) Depreciation and amortisation expense	172.64	166.45	161.96	339.09	320.07	654.32
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	544.69	457.74	587.49	1,002.43	1,089.94	2,050.13
	h) Other Expenses	147.51	147.72	156.51	295.23	298.65	501.14
	<b>Total expenses</b>	<b>1,290.29</b>	<b>1,230.75</b>	<b>1,352.57</b>	<b>2,521.04</b>	<b>2,581.31</b>	<b>4,811.54</b>
3	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>(470.16)</b>	<b>(287.06)</b>	<b>(893.31)</b>	<b>(757.22)</b>	<b>(1,724.55)</b>	<b>(2,612.72)</b>
4	Exceptional Items -(Ref Note:6)	745.66	-	-	745.66	600.00	600.00
5	<b>Profit before Tax (3-4)</b>	<b>275.50</b>	<b>(287.06)</b>	<b>(893.31)</b>	<b>(11.56)</b>	<b>(1,124.55)</b>	<b>(2,012.72)</b>
6	<b>Tax Expenses</b>						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
7	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>275.50</b>	<b>(287.06)</b>	<b>(893.31)</b>	<b>(11.56)</b>	<b>(1,124.55)</b>	<b>(2,012.72)</b>
8	<b>Other Comprehensive Income</b>						
8.a	(i) Items that will not be reclassified to profit or loss	4.74	4.75	(3.76)	9.49	(7.52)	18.99
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>4.74</b>	<b>4.75</b>	<b>(3.76)</b>	<b>9.49</b>	<b>(7.52)</b>	<b>18.99</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>280.24</b>	<b>(282.31)</b>	<b>(897.07)</b>	<b>(2.07)</b>	<b>(1,132.07)</b>	<b>(1,993.73)</b>
10	<b>Paid-up equity share capital</b>	<b>2,180.74</b>	<b>2,180.74</b>	<b>1,453.82</b>	<b>2,180.74</b>	<b>1,453.82</b>	<b>2,180.74</b>
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	<b>Other Equity</b>						<b>83,163.71</b>
12	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>						
	a) Basic	0.13	(0.13)	(0.61)	(0.01)	(0.77)	(1.13)
	b) Diluted	0.13	(0.13)	(0.61)	(0.01)	(0.77)	(1.13)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



PART - I		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the Six Months period ended		For the year ended
		30/09/2023	30/06/2023	30/09/2022	30/09/2023	30/09/2022	31/03/2023
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	305.96	379.73	438.65	685.69	792.57	1,353.92
	Other Income	514.17	563.96	20.61	1,078.13	64.19	844.90
	<b>Total income</b>	<b>820.13</b>	<b>943.69</b>	<b>459.26</b>	<b>1,763.82</b>	<b>856.76</b>	<b>2,198.82</b>
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	444.87	528.03	507.85	972.90	992.98	1,862.09
	d) Finance costs	4.19	5.12	6.94	9.31	17.11	28.91
	e) Depreciation and amortisation expense	172.64	166.45	161.96	339.09	320.07	654.32
	f) Manufacturing Expenses	-	-	-	-	-	-
	g) R & D Expenses	2,049.73	2,478.63	1,934.46	4,528.36	3,759.42	11,535.10
	h) Other Expenses	162.38	174.51	166.20	336.89	317.95	545.18
	<b>Total expenses</b>	<b>2,833.81</b>	<b>3,352.74</b>	<b>2,777.41</b>	<b>6,186.55</b>	<b>5,407.53</b>	<b>14,625.60</b>
3	Profit before exceptional items , Tax (1-2)	(2,013.68)	(2,409.05)	(2,318.15)	(4,422.73)	(4,550.77)	(12,426.78)
4	Exceptional Items -(Ref Note:6)	745.66	-	-	745.66	600.00	600.00
5	Profit before Tax (3-4)	(1,268.02)	(2,409.05)	(2,318.15)	(3,677.07)	(3,950.77)	(11,826.78)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
7	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>(1,268.02)</b>	<b>(2,409.05)</b>	<b>(2,318.15)</b>	<b>(3,677.07)</b>	<b>(3,950.77)</b>	<b>(11,826.78)</b>
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	4.75	4.75	(3.76)	9.50	(7.52)	18.99
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>4.75</b>	<b>4.75</b>	<b>(3.76)</b>	<b>9.50</b>	<b>(7.52)</b>	<b>18.99</b>
9	<b>Total Comprehensive Income for the period ( 7+ 8)</b>	<b>(1,263.27)</b>	<b>(2,404.30)</b>	<b>(2,321.91)</b>	<b>(3,667.57)</b>	<b>(3,958.29)</b>	<b>(11,807.79)</b>
10	Paid-up equity share capital Face Value of the Share	2,180.74 Re.1.00	2,180.74 Re.1.00	1,453.82 Re.1.00	2,180.74 Re.1.00	1,453.82 Re.1.00	2,180.74 Re.1.00
11	Other Equity	-	-	-	-	-	35,351.19
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(0.58)	(1.10)	(1.59)	(1.69)	(2.72)	(6.63)
	b) Diluted	(0.58)	(1.10)	(1.59)	(1.69)	(2.72)	(6.63)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



**NOTES:-**

- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 04, 2023 . The results for the quarter ended September 30, 2023 has been reviewed by our statutory auditors
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences , Inc
- 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 5) The Company has allotted 72691239 equity shares amounting to Rs.39980.18 lakhs through rights issue on November 16,2022.

**Summary of Utilisation of Proceeds of Rights issue**

Particulars	Amount Rs. In lakhs
Amout Raised through Rights Issue of Shares	39980.18
Less: Rights Issue Expenses	-280.00
Less: Amount Utilised	-18051.16
<b>Balance Amount</b>	<b>21649.02</b>

6) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other materials in the effected buildings were damaged. The insurance claim was settled and the Company has received total payment from the Insurnace Company of Rs.19.45 Crores (including the final payment of Rs.7.45 Crores received during the second quarter under review).

7) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad  
Date : November 04,2023



For SUVEN LIFE SCIENCES LTD

*Venkat Jasti*

**VENKAT JASTI**  
Chairman & CEO  
DIN: 00278028



# SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

## Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	30/09/2023	31/03/2023	30/09/2023	31/03/2023
<b>A ASSETS</b>	<b>UN AUDITED</b>	<b>AUDITED</b>	<b>UN AUDITED</b>	<b>AUDITED</b>
<b>1 Non-current assets</b>				
(a) Property, Plant and Equipment	3,310.59	3,573.28	3,313.28	3,573.28
(b) Capital Work-in-Progress	-	-	-	-
(c) Other Intangible Assets	18.49	19.81	18.49	19.81
(d) Right of use Assets	89.56	128.33	89.56	128.33
(e) Financial Assets				
I. Investments	52,724.97	48,185.61	-	-
II. Other financial assets	10,001.50	10,001.50	10,001.50	10,001.50
(f) Other Non-current Assets	5.79	9.49	5.79	9.49
<b>Total Non-Current assets</b>	<b>66,150.90</b>	<b>61,918.02</b>	<b>13,428.62</b>	<b>13,732.41</b>
<b>2 Current assets</b>				
Inventories	73.68	-	73.68	-
(a) Financial Assets				
I. Investments in mutual funds	6,443.57	4,633.89	6,443.57	4,633.89
II. Trade Receivables	99.91	80.74	99.91	80.74
III. Cash and Cash equivalents	364.20	2,669.52	1,858.34	3,701.91
IV. Bank balances otherthan (III) above	10,538.48	14,726.16	10,538.48	14,726.16
V. Other financial assets	938.88	476.68	938.88	476.68
(b) Current Tax asset(net)	705.51	696.96	705.51	696.96
(c) Other current assets	938.65	842.31	938.65	842.31
<b>Total Current assets</b>	<b>20,102.88</b>	<b>24,126.26</b>	<b>21,597.02</b>	<b>25,158.65</b>
<b>TOTAL - ASSETS</b>	<b>86,253.78</b>	<b>86,044.28</b>	<b>35,025.64</b>	<b>38,891.06</b>
<b>B EQUITY AND LIABILITIES</b>				
<b>1 EQUITY</b>				
(a) Equity Share Capital	2,180.74	2,180.74	2,180.74	2,180.74
(b) Other Equity	83,161.64	83,163.71	31,662.05	35,351.19
<b>Total Equity</b>	<b>85,342.38</b>	<b>85,344.45</b>	<b>33,842.79</b>	<b>37,531.93</b>
<b>2 LIABILITIES</b>				
(a) Financial Liabilities				
I. Lease Liabilities	12.07	57.92	12.07	57.92
II. Long-term Borrowings	-	-	-	-
(b) Provisions	188.24	188.25	188.24	188.25
(c) Other non current liabilities	-	-	-	-
<b>Total non-current liabilities</b>	<b>200.31</b>	<b>246.17</b>	<b>200.31</b>	<b>246.17</b>
<b>Current liabilities</b>				
(a) Financial Liabilities				
I. Lease Liabilities	105.02	102.60	105.02	102.60
II. Borrowings	-	-	-	-
III. Trade payables				
a) To Micro & Small Enterprises	15.98	25.44	15.98	25.44
b) Other than Micro & Small Enterprises	335.77	141.04	335.77	141.04
IV. Other Financial Liabilities	53.14	36.13	318.22	686.60
(b) Provision Employee benefits	162.75	102.75	162.75	102.75
(c) Other Current liabilities	38.43	45.70	44.80	54.53
<b>Total - Current liabilities</b>	<b>711.09</b>	<b>453.66</b>	<b>982.54</b>	<b>1,112.96</b>
<b>Total Liabilities</b>	<b>911.40</b>	<b>699.83</b>	<b>1,182.85</b>	<b>1,359.13</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>86,253.78</b>	<b>86,044.28</b>	<b>35,025.64</b>	<b>38,891.06</b>

For Suvan Life Sciences Ltd

Place: Hyderabad

Date: November 04, 2023

Venkat Jasti  
Chairman & CEO



# SUVEN LIFE SCIENCES LTD

## Unaudited Standalone Cash flow statement

(Rs.In lakhs)

Particulars	For the half year ended September 30, 2023	For the half year ended September 30, 2022
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax	(11.56)	(1,124.55)
<b>Adjustments :</b>		
Depreciation and amortisation expense	303.26	283.71
Interest Income	867.97	-
Finance Cost	9.31	17.11
Gain on Insurance receipt	(745.66)	(600.00)
Unrealised/sale of Gain on Current Investment	(184.84)	(40.20)
<b>Operating profit before working capital changes</b>	<b>238.48</b>	<b>(1,463.93)</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>		
Trade Receivables	(19.17)	(4.05)
Inventories	(73.68)	-
Other non current assets	42.47	75.91
Other current assets	649.32	423.05
<b>Adjustments for Increase/(decrease) in operating liabilities</b>		
Trade Payables	185.27	167.39
Long term provisions	-	55.00
Short term provision	69.50	62.48
Other financial liabilities	17.01	(25.09)
Other current liabilities	(7.27)	(22.75)
<b>Cash generated from operating activities</b>	<b>1,101.93</b>	<b>(731.99)</b>
Income taxes paid (net of refunds)	8.55	35.24
<b>Net Cash flows from operating activities</b>	<b>1,093.38</b>	<b>(767.23)</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(39.26)	(248.32)
Other financial assets	(462.19)	-
Interest received	(867.97)	-
Changes in Investments	(4,539.36)	(2,747.73)
Sale/(purchase) of mutual funds	(1,624.84)	41.45
Bank balances not considered as cash and cash equivalents	4,187.68	0.78
<b>Net cash flow from /( used in) investing activities</b>	<b>(3,345.94)</b>	<b>(2,953.82)</b>
<b>C. Cash flows from financing activities</b>		
(Repayment)/Proceeds from borrowings	-	4,951.57
Changes In Lease Liability	(43.44)	(75.89)
Finance Cost	(9.31)	(14.41)
<b>Net cash flow from /(used In) financing activities</b>	<b>(52.75)</b>	<b>4,861.27</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(2,305.31)</b>	<b>1,140.22</b>
Cash and cash equivalents as at the beginning of the year	2,669.52	290.04
<b>Cash and cash equivalents at the end of the year</b>	<b>364.21</b>	<b>1,430.26</b>

Place : Hyderabad  
Date : November 04, 2023



For Suven Life Sciences Ltd

*Venkat Jasti*

**Venkat Jasti**  
Chairman & CEO  
DIN: 00278028

**SUVEN LIFE SCIENCES LTD**

**Unaudited Consolidated Cash flow statement**

(Rs.In lakhs)

Particulars	For the half year ended September 30, 2023	For the half year ended September 30, 2022
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax	(3,677.07)	(3,950.77)
<b>Adjustments :</b>		
Depreciation and amortisation expense	303.26	283.71
Interest Income	867.97	-
Finance Cost	9.31	17.11
Gain on Insurance receipt	(745.66)	(600.00)
Unrealised/sale of Gain on Current Investment	(184.84)	(40.20)
<b>Operating profit before working capital changes</b>	<b>(3,427.03)</b>	<b>(4,290.15)</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>		
Trade Receivables	(19.17)	(4.05)
Inventories	(73.68)	-
Other non current assets	42.47	75.91
Other current assets	649.32	423.05
<b>Adjustments for Increase/(decrease) in operating liabilities</b>		
Trade Payables	185.27	167.39
Long term provisions	-	55.00
Short term provision	69.50	62.48
Other financial liabilities	(368.38)	73.78
Other current liabilities	(9.72)	(22.75)
<b>Cash generated from operating activities</b>	<b>(2,951.42)</b>	<b>(3,459.34)</b>
Income taxes paid (net of refunds)	8.55	35.24
<b>Net Cash flows from operating activities</b>	<b>(2,959.97)</b>	<b>(3,494.58)</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(41.95)	(248.32)
Other financial assets	(462.20)	-
Interest received	(867.97)	-
Sale/(purchase) of mutual funds	(1,624.84)	41.45
Foreign currency translation reserve	(21.56)	(9.00)
Bank balances not considered as cash and cash equivalents	4,187.68	0.78
<b>Net cash flow from /(used in) investing activities</b>	<b>1,169.16</b>	<b>(215.09)</b>
<b>C. Cash flows from financing activities</b>		
(Repayment)/Proceeds from borrowings	-	4,951.57
Changes In Lease Liability	(43.44)	(75.89)
Finance Cost	(9.31)	(14.41)
<b>Net cash flow from /(used In) financing activities</b>	<b>(52.75)</b>	<b>4,861.27</b>
Net increase/(decrease) in cash and cash equivalents	(1,843.56)	1,151.60
Cash and cash equivalents as at the beginning of the year	3,701.91	527.35
<b>Cash and cash equivalents at the end of the year</b>	<b>1,858.35</b>	<b>1,678.95</b>

Place : Hyderabad  
Date : November 04, 2023



For Suven Life Sciences Ltd

*Venkat Jasti*

**Venkat Jasti**  
Chairman & CEO  
DIN: 00278028